Principles of personalized medicine and modern pharmaceutical technologies to optimize levodopa therapy of Parkinson's disease
Levodopa (3-hydroxy-L-tyrosine, the levorotatory isomerof 3,4-dihydroxyphenylalanine) is a biological precursor of the neurotransmitter dopamine and has been the "gold standard" in the treatment of Parkinsons disease for over 50 years. The widespread use of levodopa in clinical practice ha...
Main Authors: | Denis А. Abaimov, Ekaterina Yu. Fedotova, Vsevolod V. Poleshchuk, Maksim N. Andreev, Oxana P. Trifonova, Petr G. Lokhov, Sergey N. Illarioshkin |
---|---|
Format: | Article |
Language: | English |
Published: |
Research Center of Neurology
2021-06-01
|
Series: | Анналы клинической и экспериментальной неврологии |
Subjects: | |
Online Access: | https://annaly-nevrologii.com/journal/pathID/article/viewFile/749/580 |
Similar Items
-
Gender Differences in Levodopa Pharmacokinetics in Levodopa-Naïve Patients With Parkinson’s Disease
by: Valeria Conti, et al.
Published: (2022-05-01) -
Levodopa in the treatment of Parkinson’s disease: an old drug still going strong
by: Werner Poewe, et al.
Published: (2010-08-01) -
Mucuna pruriens as adjunct therapy to levodopa in advanced Parkinson’s disease
by: Fernando Botello-Villagrana, et al.
Published: (2021-01-01) -
Profile of inhaled levodopa and its potential in the treatment of Parkinson’s disease: evidence to date
by: Patel AB, et al.
Published: (2018-11-01) -
Discinesias induzidas por levodopa em 176 pacientes com doença de Parkinson Levodopa-induced dyskinesias in 176 parkisonian patients
by: Maria Sheila G. Rocha, et al.
Published: (1995-12-01)